SEATTLE, April 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida:
- Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET. "B lymphocytes are activated during the course of sipuleucel-T treatment, leading to an antigen-specific humoral response." Poster presentation.
- Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET. "Evidence of T lymphocyte activation following sipuleucel-T treatment." Poster presentation.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and has manufacturing facilities in New Jersey, Georgia and California. Dendreon is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
SOURCE Dendreon Corporation